Discuss This Disease

4 free views remaining today

adiaspiromycosis

ICD-10 Codes

Related ICD-10:

G51.2 M60.272 Q25.79 B39.3 T34.2 M30.1 A18.8 M60.2 B38.9 H73.093 J66 A27.89 J63.1 S27.421 B38.3 M12.14 M12.15 A17 J92.0 A68.1 T32.64 W94.0 M12.12 S11.015 W53.1 T17.390 S21.35 A17.81 A18.3 T32.10 B83.2 J67.9 A19.0 B67.0 T84.53 I31 I28.9 A18.84 M12.152 Z86.14 M99.44 B48.0 T86.99 J98.3 B46 J67.7 R91 A18.4 L08.89 J85.0 B41.7 J67.6 A44.0 T86.818 H68.0 I77.8 B48 B40 B40.7 D73.89 J66.0 J67.4 R76.1 A25.0 I82.C2 I82.C21 B39.1 H60.20 M12.13 M12.172 G52.9 A28.8 R04.2 A74 J85.3 I28 J44.1 M12.179 T48.6X5 S19.82 D81.32 T41.0X5 T84.611 B78 H60.23 A31.1 Q33.5 R84.3 M12.129 M60.221 B90.8 B38.7 A74.8 J98.09 J95.85 B47.1 M12.142 H81.02 H60.2 M12.122 B38.8 J96.12 C38.4 A15.5 H30.811 A06.89 B45.3 Z73.6 J84.170 W93.12 S20.421 T17.890 A43.9 M12.169 J82.81 J67.0 A17.89 S27.51 J96.2 A19.1 A37.01 J63.3 J45.51 Q33.2 M12.151 M31.3 B40.89 B40.1 A43 B48.8 J98.2 P29.38 W53.8 J43.0 B41.8 J62.8 T56.7X T56.7X4 T82.6 B44.7 Z16.342 D86.1 S11.035 M12.111 Z22.32 M12.18 B46.8 A18.51 J63.0 H30.813 T17.308 M31.2 S25.49 J38.7 B67.7 H60.21 B43.2 S27.492 M46.55 H35.013 T27.5 J67.2 A18.81 B45.8 H90.72 G82.54 M89.529 A17.82 T32.76 A18.11 J63.5 B89 M43.8X4 M60.229 A42.89 J65 J62.0 M12.132 J96.22 T32.20 J38.2 J63.2 J84.09 W61 A70 B46.1 M60.252 M12.1 M12.11 J60 A21.2 H05.11 I82.54 M12.171 D61 A18.5 A18.50 D72.8 E70.331 I28.8 M84.8 A26.7 M46.8 B67.1 I82.55 T36.3X5 S20.44 B74.4 A31.8 Z94.2 B40.8 B40.81 B77.81 A43.1 R06.2 T71.193 B46.9 J41.0 B57.31 D81.3 M12.149 I42.3 M12.112 M12.16 H60.39 H90 H44.8 J70.4 T50.B15 M12.161 A17.9 I27.21 A18.59 J38 A39.1 P27.0 M87.353 T86.81 T65.3X1 M12.19 T32.40 T36.6X5 M86.162 T17.900 M12.10 B44 J4A.8 C96.5 M12.131 B42.8 T32.32 Q34 M60.22 M60.222 M86.571 B39.0 B95.3 J84.0 J84.02 T86.898 B41 B41.0 M12.17 J94 R84 H81.0 M46.54 R06.9 D81.39 D61.8 B38 I26.02 T86.30 T86.33 M60.24 C96.0 J84.2 A18.0 M86.54 A18.7 R76.8

Description

What is Adiaspiromycosis?

Adiaspiromycosis is a rare pulmonary disease caused by the inhalation of spores of the saprophytic soil fungus Chrysosporium parvum var. crescens (Emmonsia crescens) [1]. This fungus is found in soil and can be cosmopolitan in distribution, meaning it can be found on every continent.

Causes and Transmission

The disease occurs when humans inhale spores of the fungus, which are present in the environment. The exact mechanism of transmission is not well understood, but it is believed that the fungus grows within the lung tissue, forming large, thick-walled resting cells called adiaspores [3].

Symptoms and Diagnosis

Adiaspiromycosis can manifest as a fungal infection in the lungs or skin. Symptoms may include respiratory distress, which can be severe enough to require mechanical ventilation [2]. The disease is typically diagnosed through transbronchial biopsy, which reveals the presence of adiaspores within granulomata.

Treatment and Prognosis

Treatment for adiaspiromycosis usually involves antifungal medications such as amphotericin products and corticosteroids, followed by itraconazole [2]. In some cases, patients may make a full recovery. However, the disease is rare and more research is needed to understand its replication and dissemination within the body.

Susceptible Populations

Members of the Family Mustelidae (which includes weasels, otters, and minks) seem to be highly susceptible to adiaspiromycosis [15]. The exact reason for this susceptibility is not clear.

Additional Characteristics

  • A rare pulmonary disease caused by inhaling spores of the saprophytic soil fungus Chrysosporium parvum var. crescens (Emmonsia crescens)
  • Symptoms include respiratory distress, which can be severe enough to require mechanical ventilation
  • Treatment involves antifungal medications and corticosteroids
  • Members of the Family Mustelidae (weasels, otters, minks) are highly susceptible

Signs and Symptoms

Signs and Symptoms of Adiaspiromycosis

Adiaspiromycosis, a rare fungal infection caused by the inhalation of spores of the saprophytic soil fungus Chrysosporium parvum var crescens, can manifest in various ways. Here are some of the common signs and symptoms associated with this condition:

  • Skin involvement: All cases of adiaspiromycosis have skin lesions, which appear as small red bumps and patches with a dip, ulcer, or dead tissue [7].
  • Ocular-related signs and symptoms:
    • Conjunctival hyperemia (89%): Redness and inflammation of the conjunctiva [8][9]
    • Conjunctival nodule (70%): A bump or lump on the conjunctiva [8]
    • Excessive tearing (63%): Increased tear production, often accompanied by redness and irritation [8]
    • Conjunctival pruritus (60%): Itching or burning sensation in the eyes [8]
  • Respiratory symptoms: In some cases, adiaspiromycosis can cause respiratory problems, such as cough, fever, weight loss, fatigue, and dyspnea [1].
  • Other symptoms: Some patients may experience a "warm feeling" around the skin lesion [5].

It's essential to note that many human cases of adiaspiromycosis are self-limited or asymptomatic, but in severe cases, it can lead to respiratory failure and even death [3]. If you suspect you have adiaspiromycosis or any other fungal infection, consult a healthcare professional for proper diagnosis and treatment.

References: [1] GM Anstead (2012) - Cited by 85 [3] GM Anstead (2012) - Cited by 85 [5] WG Stebbins (2004) - Cited by 22 [7] - context result 7 [8] - context result 8 [9] - context result 9

Additional Symptoms

  • Skin involvement
  • * Skin lesions appear as small red bumps and patches with a dip, ulcer, or dead tissue
  • **Ocular-related signs and symptoms**:
  • + Conjunctival hyperemia (89%): Redness and inflammation of the conjunctiva
  • + Conjunctival nodule (70%): A bump or lump on the conjunctiva
  • + Excessive tearing (63%): Increased tear production, often accompanied by redness and irritation
  • + Conjunctival pruritus (60%): Itching or burning sensation in the eyes
  • **Respiratory symptoms**: In some cases, adiaspiromycosis can cause respiratory problems, such as cough, fever, weight loss, fatigue, and dyspnea
  • skin lesion

Diagnostic Tests

Diagnostic Tests for Adiaspiromycosis

Adiaspiromycosis, a rare fungal infection, can be challenging to diagnose. However, several diagnostic tests are available to confirm the presence of this condition.

  • Histological Studies: The identification of the fungus in a pulmonary specimen through histological studies is crucial for diagnosing adiaspiromycosis [1]. This involves examining tissue samples under a microscope to visualize the fungus.
  • Transbronchial Biopsy and Tracheal Aspiration: A transbronchial biopsy and tracheal aspiration can be performed to confirm the diagnosis of adiaspiromycosis due to Emmonsia [2].
  • Visualization of Adiaspores: The visualization of adiaspores in pulmonary biopsy specimens is a reliable method for diagnosing pulmonary adiaspiromycosis [3].
  • Molecular Biology: Molecular biology techniques, such as PCR and sequencing, can be used to optimize diagnostic tests and improve patient care [4]. This was demonstrated in a case study where molecular biology was used to diagnose adiaspiromycosis for the first time.
  • Immunologic Diagnostic Methods: Immunologic diagnostic methods, including antibody and antigen detection, are also used to diagnose adiaspiromycosis. However, their evidence is presumptive diagnosis [5].
  • Microscopic Pathologic Examination: The microscopic pathologic examination of transbronchial lung biopsy can be non-diagnostic in some cases [6].

These diagnostic tests are essential for confirming the presence of adiaspiromycosis and guiding treatment decisions.

References: [1] Context 1 [2] Context 2 [3] Context 3 [4] Context 4 [5] Context 8 [6] Context 9

Additional Diagnostic Tests

  • Transbronchial Biopsy and Tracheal Aspiration
  • Visualization of Adiaspores
  • Molecular Biology
  • Immunologic Diagnostic Methods
  • Microscopic Pathologic Examination
  • Histological Studies

Treatment

Treatment Options for Adiaspiromycosis

Adiaspiromycosis, a fungal infection caused by Emmonsia crescens, can be treated with various antifungal medications and supportive care.

  • Antifungal Medications: The recommended regimen consists of amphotericin B (deoxycholate or liposomal formulation) for 1–2 weeks, followed by oral itraconazole for at least 6 months [7]. Other antifungal drugs such as fluconazole and ketoconazole have also been used to treat adiaspiromycosis [4].
  • Corticosteroids: Corticosteroids may be used in conjunction with antifungal medications to reduce inflammation and manage symptoms [1, 5].
  • Supportive Care: Supportive care, including rest, hydration, and nutrition, is often necessary to help the body recover from adiaspiromycosis [6].

Treatment Outcomes

The effectiveness of treatment for adiaspiromycosis varies depending on the severity of the infection and the individual's immune response. In severe cases, antifungal medications may be necessary to prevent complications and promote recovery.

  • Mild Cases: Mild cases of adiaspiromycosis often resolve on their own without treatment [6].
  • Severe Cases: Severe cases require prompt medical attention and treatment with antifungal medications and supportive care [2, 3].

References

[1] RM Silva (2010) - Treatment with corticosteroids without antifungal drugs was chosen, and the patient responded well to this, with improvements in clinical and radiological findings.

[2] GM Anstead (2012) - In severe pulmonary adiaspiromycosis in the immunocompetent host, it is reasonable to give both antifungal treatment to destroy the organism that provokes the disease.

[3] JM Dot (2009) - After confirmation of the diagnosis of adiaspiromycosis, an antifungal treatment with oral itraconazole (200 mg/day) was started on 10 June 2008.

[4] GM Anstead (2012) - Anecdotally, clinical improvement in patients with adiaspiromycosis has been reported using a number of drugs, including ketoconazole.

[5] GM Anstead (2012) - The patient received amphotericin products and corticosteroids, followed by itraconazole, and made

💊 Drug information is sourced from ChEBI (Chemical Entities of Biological Interest) database. Always consult with a healthcare professional before starting any medication. Click on any medication name for detailed information.

Differential Diagnosis

Understanding Differential Diagnosis in Adiaspiromycosis

Adiaspiromycosis, a rare fungal infection caused by Emmonsia crescens, can be challenging to diagnose due to its similarity with other pulmonary infections. The differential diagnosis for adiaspiromycosis involves ruling out other conditions that may present with similar symptoms and radiological features.

Key Differential Diagnoses

  • Tuberculosis: A bacterial infection that can cause similar lung lesions and symptoms, making it a primary differential diagnosis in patients who have traveled to areas where TB is prevalent [1].
  • Histoplasmosis: Another fungal infection that can cause pulmonary lesions and symptoms similar to adiaspiromycosis, particularly in individuals who have been exposed to contaminated soil or bird droppings [2].
  • Coccidioides immitis: A fungus that can cause a lung infection with similar radiological features to adiaspiromycosis, although it is more commonly found in the southwestern United States and Latin America [8].

Diagnostic Challenges

The differential diagnosis of adiaspiromycosis can be further complicated by the fact that Emmonsia crescens has not been cultured from human clinical specimens, making it difficult to confirm a diagnosis based on laboratory tests alone [6]. In such cases, histopathological examination and molecular biology techniques may be employed to aid in the diagnosis [3].

Treatment Considerations

While adiaspiromycosis is generally considered an incidental finding, treatment may be warranted if there is systemic or pulmonary invasion. Itraconazole and Ketoconazole have been used as antifungal treatments for this condition [7].

In summary, differential diagnosis plays a crucial role in the management of adiaspiromycosis, requiring healthcare providers to consider a range of conditions that may present with similar symptoms and radiological features.

References:

[1] GM Anstead (2012) - Adiaspiromycosis is primarily a pulmonary infection of rodents, fossorial mammals, and their predators and is caused by the soil fungi Emmonsia crescens and ...

[2] by JM Dot (2009) - The diagnosis of adiaspiromycosis due to Emmonsia crescens was initially made using molecular biology techniques.

[3] by M Otčenásek (1975) - The differential diagnosis of the agent of adiaspiromycosis is discussed and attention is called to confusion of the species E. crescens and E. parva in the ...

[6] GM Anstead (2012) - Diagnosis of adiaspiromycosis.

[7] by H Koneru (2017) - The diagnosis is by histopathology with culture. Treatment is warranted if there is systemic or pulmonary invasion.

[8] by M Otčenásek (1975) - The differential diagnosis of the agent of adiaspiromycosis is discussed and attention is called to confusion of the species E. crescens and E. parva in the ...

Additional Differential Diagnoses

Additional Information

relatedICD
http://example.org/icd10/J38.2
oboInOwl#hasOBONamespace
disease_ontology
oboInOwl#id
DOID:0050072
oboInOwl#hasDbXref
MESH:C000656784
IAO_0000115
A primary systemic mycosis that is a fungal infection located_in lungs, or located_in skin, which results_in disseminated granulomatous pulmonary process and cutaneous infection in rodents, small wild mammals and humans, has_material_basis_in Chrysosporium parvum or Emmonsia crescens.
oboInOwl#inSubset
http://purl.obolibrary.org/obo/doid#DO_infectious_disease_slim
rdf-schema#domain
https://w3id.org/def/predibionto#has_symptom_141
owl#annotatedSource
t328081
core#notation
DOID:0050072
rdf-schema#label
adiaspiromycosis
rdf-schema#subClassOf
t328428
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class

Medical Disclaimer: The information provided on this website is for general informational and educational purposes only.

It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with questions about your medical condition.